全文获取类型
收费全文 | 72篇 |
免费 | 5篇 |
国内免费 | 14篇 |
专业分类
耳鼻咽喉 | 2篇 |
妇产科学 | 1篇 |
基础医学 | 1篇 |
临床医学 | 14篇 |
内科学 | 2篇 |
皮肤病学 | 1篇 |
神经病学 | 1篇 |
外科学 | 14篇 |
综合类 | 19篇 |
预防医学 | 20篇 |
药学 | 12篇 |
中国医学 | 3篇 |
肿瘤学 | 1篇 |
出版年
2024年 | 1篇 |
2023年 | 12篇 |
2022年 | 5篇 |
2021年 | 3篇 |
2020年 | 2篇 |
2019年 | 6篇 |
2018年 | 4篇 |
2017年 | 4篇 |
2016年 | 4篇 |
2015年 | 3篇 |
2014年 | 4篇 |
2013年 | 4篇 |
2012年 | 6篇 |
2010年 | 2篇 |
2009年 | 4篇 |
2008年 | 16篇 |
2007年 | 1篇 |
2006年 | 1篇 |
2005年 | 2篇 |
2004年 | 1篇 |
2003年 | 2篇 |
2002年 | 1篇 |
2001年 | 1篇 |
2000年 | 2篇 |
排序方式: 共有91条查询结果,搜索用时 15 毫秒
1.
Objective To investigate the effect and mechanism by which PPARγ ligand, rosiglitasone, regulates the expression of CD40 and intercellular adhesion molecule 1 (ICAM-1) in the rat peritoneal mesothelial cells (RPMCs) induced by lipopolysaccharide (LPS). Methods RPMCs were harvested from Sprague-Dawley rat peritoneal cavity and maintained under defined in vitro conditions. The cells were randomly divided into groups as follows: medium, LPS (5 mg/L), LPS (5 mg/L)+BAY11-7085(5 μmol/L, NF-κB inhibitor), rosiglitazone (10 μmol/L or 20 μmol/L, peroxisome proliferator-activated receptor γ activator), LPS (5 mg/L)+rosiglitazone (10 μmol/L)+GW9662 (3 μmol/L, peroxisome proliferator-aetivatcd receptor γ antagonist), and LPS (5 mg/L)+vehicle (DMSO 0.2 ml/L). The expressions of CD40 and ICAM-1 RNA in RPMCs were examined by RT-PCR after 3 hour treatment, and the protein expressions of CD40, ICAM-1, p-NF-κB p65 and p-IκBα were examined by Western blot or immunofluorescence after 24 hour treatment. Results Following treatment with LPS, both the expressions of CD40 and ICAM-1 protein in RPMCs were up-regulated significantly (P<0.05), and the phosphoralation of p65 was increased greatly (1.10±0.17 vs 0.55±0.06, P<0.05). BAY11-7085 (5 μmol/L) significantly decreased the protein expression of p-p65 (0.22±0.11 vs 1.10±0.17, P<0.01), CD40 (0.34±0.02 vs 0.50±0.06, P<0.05) and ICAM-1 (0.35±0.16 vs 0.74±0.03, P<0.05). Pretreated with rosiglitazone for 3 h then added with LPS for 1 h, the levels of p-p65, CD40 and ICAM-1 in RPMCs were significantly decreased compared with those of LPS group (0.77±0.08 vs 0.90±0.10, P相似文献
2.
3.
4.
5.
6.
7.
Objective To investigate the effect and mechanism by which PPARγ ligand, rosiglitasone, regulates the expression of CD40 and intercellular adhesion molecule 1 (ICAM-1) in the rat peritoneal mesothelial cells (RPMCs) induced by lipopolysaccharide (LPS). Methods RPMCs were harvested from Sprague-Dawley rat peritoneal cavity and maintained under defined in vitro conditions. The cells were randomly divided into groups as follows: medium, LPS (5 mg/L), LPS (5 mg/L)+BAY11-7085(5 μmol/L, NF-κB inhibitor), rosiglitazone (10 μmol/L or 20 μmol/L, peroxisome proliferator-activated receptor γ activator), LPS (5 mg/L)+rosiglitazone (10 μmol/L)+GW9662 (3 μmol/L, peroxisome proliferator-aetivatcd receptor γ antagonist), and LPS (5 mg/L)+vehicle (DMSO 0.2 ml/L). The expressions of CD40 and ICAM-1 RNA in RPMCs were examined by RT-PCR after 3 hour treatment, and the protein expressions of CD40, ICAM-1, p-NF-κB p65 and p-IκBα were examined by Western blot or immunofluorescence after 24 hour treatment. Results Following treatment with LPS, both the expressions of CD40 and ICAM-1 protein in RPMCs were up-regulated significantly (P<0.05), and the phosphoralation of p65 was increased greatly (1.10±0.17 vs 0.55±0.06, P<0.05). BAY11-7085 (5 μmol/L) significantly decreased the protein expression of p-p65 (0.22±0.11 vs 1.10±0.17, P<0.01), CD40 (0.34±0.02 vs 0.50±0.06, P<0.05) and ICAM-1 (0.35±0.16 vs 0.74±0.03, P<0.05). Pretreated with rosiglitazone for 3 h then added with LPS for 1 h, the levels of p-p65, CD40 and ICAM-1 in RPMCs were significantly decreased compared with those of LPS group (0.77±0.08 vs 0.90±0.10, P相似文献
8.
目的通过成分献血(机采血小板)者与全血献血者体内血浆D-二聚体含量的比对观察,探讨二者在降低血栓性心脑血管疾病发生意义上的临床价值。方法采用全自动血凝分析透视光免疫浊度法对不同年龄段的360名健康献血者,进行体内血浆D-二聚体的含量测定,并进行比对观察。结果180名成分献血(机采血小板)者体内D-二聚体的含量显著低于180名全血献血者,2组献血者不同年龄血浆D-二聚体含量差异均有统计学意义(P〈0.01)。结论在降低血栓性疾病发生意义上,成份献血更优于传统的全血献血。 相似文献
9.
目的:研究石榴皮中总黄酮的微波提取最佳工艺条件并测定其含量。方法:采用微波提取法提取石榴皮中总黄酮,通过单因素试验,考察了微波功率、乙醇体积分数、料液比、微波提取时间4个因素对总黄酮提取的影响,通过正交试验进一步优化提取工艺,运用硝酸铝显色法测定总黄酮含量。结果:微波提取法提取石榴皮中总黄酮的最佳工艺为乙醇体积分数60%,料液比为1∶25,微波提取时间为120 s;微波功率对总黄酮提取无显著影响,其余3个因素对总黄酮提取的影响依次为乙醇体积分数>料液比>微波提取时间;总黄酮平均含量为6.70%。结论:采用微波提取法提取石榴皮中的总黄酮,具有快速、高效、节能、不破坏有效成分等特点,具有良好的应用前景。 相似文献
10.
目的 观察黄芪甲苷对糖尿病KKAy小鼠肾组织转化生长因子β1(TGF-β1)、SMAD2/3、q-平滑肌肌动蛋白(α-SMA)表达的影响,探讨其延缓肾脏纤维化的可能机制.方法 雄性C57BL/6J小鼠10只作为对照组,20只2型糖尿病模型KKAy小鼠予以高脂饮食至14周,随机数字法分为模型组和黄芪甲苷组,每组10只,黄芪甲苷组给予黄芪甲苷40 mg·kg-·d-1,模型组与对照组给予等量生理盐水.实验期间,各组动物自由饮食、饮水.血糖仪测量16、20、24周龄时各组小鼠的血糖水平.24周时处死,观察各组小鼠肾的病理学变化,免疫组织化学法测定TGF-β1、SMAD2/3、α-SMA的表达.结果 (1)血糖:与对照组相比,14周龄的KKAy小鼠血糖明显升高,模型组血糖在16、20、24周时血糖明显升高(P<0.05),黄芪甲苷组与其相比,血糖下降(P<0.05).(2)肾组织形态学:对照组肾小球及肾小管结构清晰,未出现肾间质纤维化,模型组肾小球系膜基质增宽,系膜细胞增多,肾小管上皮细胞细胞质空泡样变性,肾间质炎性细胞增多,黄芪甲苷组肾小管上皮细胞细胞质较少,未呈现明显的纤维化.(3)肾组织TGF-β1、SMAD2/3、α-SMA的表达:对照组TGF-β1表达微弱,而模型组TGF-β1显著表达于肾小管上皮细胞细胞质(P<0.01);与模型组相比,黄芪甲苷组TGF-β1、α-SMA表达明显下调(P<0.05);对照组肾小管与肾小球细胞核有少量磷酸化的SMAD2/3表达,模型组表达增加(P<0.01),与模型组相比,黄芪甲苷组表达减少(P<0.05).结论 黄芪甲苷通过影响TGF-β/SMADS信号通路,下调TGF-β1、α-SMA表达,改善糖尿病小鼠肾脏纤维化. 相似文献